
Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Free Report) – Equities researchers at Brookline Capital Markets issued their Q4 2026 earnings estimates for shares of Unicycive Therapeutics in a research report issued on Monday, November 16th. Brookline Capital Markets analyst K. Raja forecasts that the company will earn ($0.28) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.05) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $3.93 EPS, FY2028 earnings at $3.46 EPS, FY2029 earnings at $4.35 EPS and FY2030 earnings at $3.33 EPS.
Several other equities analysts also recently commented on UNCY. Guggenheim reissued a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Benchmark restated a “speculative buy” rating and set a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.25.
Unicycive Therapeutics Stock Down 5.1%
Unicycive Therapeutics stock opened at $3.35 on Thursday. The stock has a market cap of $93.30 million, a PE ratio of -2.01 and a beta of 1.91. Unicycive Therapeutics has a 12-month low of $3.33 and a 12-month high of $8.74. The business’s 50-day moving average price is $4.03 and its two-hundred day moving average price is $5.86.
Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.10.
Institutional Trading of Unicycive Therapeutics
Several institutional investors have recently modified their holdings of the business. Virtu Financial LLC raised its position in Unicycive Therapeutics by 412.4% during the 3rd quarter. Virtu Financial LLC now owns 59,484 shares of the company’s stock worth $279,000 after purchasing an additional 47,874 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Unicycive Therapeutics by 80.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 262,767 shares of the company’s stock worth $1,234,000 after buying an additional 117,463 shares during the period. Chicago Partners Investment Group LLC grew its position in shares of Unicycive Therapeutics by 26.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after buying an additional 5,556 shares during the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at about $36,000. Finally, Seven Fleet Capital Management LP grew its position in shares of Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares during the last quarter. Institutional investors own 40.42% of the company’s stock.
Top Unicycive Therapeutics Stories
Here are a few of the latest stories about UNCY:
- Positive Sentiment: HC Wainwright raised several 2026–27 EPS estimates, kept its Buy rating, and reiterated a $13 price target—potential support for the stock. HC Wainwright forecast article
- Negative Sentiment: A report said Unicycive’s third-quarter loss widened to $7.0 million, highlighting ongoing losses. Article on Unicycive’s Q3 loss
- Negative Sentiment: Despite raising near-term estimates, HC Wainwright cut its 2028–30 EPS forecasts substantially. Noble Financial also lowered its 2026 estimates, adding a more cautious note to the outlook. Analyst estimate reports
Unicycive Therapeutics Company Profile
Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.
Featured Articles
- Five stocks we like better than Unicycive Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
